Chris Kell

648 citations

9 papers · 447 indexed · 1 hit paper · h-index 5

Impact in

Immunology and Allergy top 5%
- Allergic Rhinitis and Sensitization
Physiology top 10%
- Asthma and respiratory diseases

Papers in ⓘ

Physiology 6
- Asthma and respiratory diseases 6
Immunology 5
- IL-33, ST2, and ILC Pathways 5

Co-authors: Dewei She (3 shared papers)Raffaella Faggioni (2 shared papers)Chad K. Oh (2 shared papers)Edward Piper (2 shared papers)Néstor A. Molfino (2 shared papers)Robert Niven (2 shared papers)Christopher E. Brightling (2 shared papers)Gregory P. Geba (2 shared papers)
Journals: European Respiratory Journal (3 papers)ERJ Open Research (1 paper)American Journal of Respiratory and Critical Care Medicine (1 paper)Advances in Therapy (1 paper)British Journal of Clinical Pharmacology (1 paper)
Partner nations: United Kingdom Singapore Sweden

In The Last Decade

Chris Kell

9 papers receiving 430 citations

Hit Papers

align trajectories log scale

A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4 2025 · 19 citations

Peers

Countries citing papers authored by Chris Kell

Since Specialization

Citations

This map shows the geographic impact of Chris Kell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Kell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Kell more than expected).

Fields of papers citing papers by Chris Kell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Kell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Kell. The network helps show where Chris Kell may publish in the future.

Co-authors

The 25 scholars most cited alongside Chris Kell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chris Kell Line = papers co-authored together Chris Kell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work
1	A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma European Respiratory Journal ·Edward Piper, Christopher E. Brightling, Robert Niven, Chad K. Oh, Raffaella Faggioni, Kwai Poon, Dewei She, Chris Kell, Richard May, Gregory P. Geba, Néstor A. Molfino	2012	290
2	A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis American Journal of Respiratory and Critical Care Medicine ·Joseph M. Parker, Ian Glaspole, Lisa Lancaster, Tarik Haddad, Dewei She, Stephanie L. Roseti, Jon P. Fiening, Ethan Grant, Chris Kell, Kevin R. Flaherty	2017	90
3	Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study Advances in Therapy ·Eric Sheldon, Martin Schwickart, Jing Li, Keunpyo Kim, Sarah Crouch, Shaista Parveen, Chris Kell, Claire Birrell	2016	36
4	A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4 European Respiratory Journal ·Dave Singh, Patricia Guller, Fred Reid, Sarah Doffman, Ulla Seppälä, Ioannis Psallidas, Rachel Moate, Rebecca Smith, Joanna Kiraga, Eulalia Jiménez, Dennis E. Brooks, Aoife Kelly, Lars H. Nordenmark, Muhammad Waqas Sadiq, Luis Mateos Caballero, Chris Kell, Maria G. Belvisi, Hitesh Pandya Hit paper breakdown →	2025	19
5	Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma European Respiratory Journal ·Edward Piper, Christopher E. Brightling, Robert Niven, Chad K. Oh, Raffaella Faggioni, Kwai Poon, Dewei She, Chris Kell, Richard May, Gregory P. Geba, Néstor A. Molfino	2011	7
6	Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease British Journal of Clinical Pharmacology ·Muhammad Waqas Sadiq, Hongtao Yu, Magnus Åstrand, Ian C. Scott, Adam Williams, Lisa Hewitt, N. E. White, Helen Killick, Monica L. Gavala, E. Suzanne Cohen, Fred Reid, Chris Kell, Hitesh Pandya, Eulalia Jiménez	2024	2
7	A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants Clinical Pharmacology in Drug Development ·Yunfei Li, Hua Zhang, Hitesh Pandya, Liyan Miao, Fred Reid, Eulalia Jiménez, Muhammad Waqas Sadiq, Rachel Moate, Alejhandra Lei, Xiaohong Zhou, Chris Kell, Junjie Ding, Guanlin Zhang, Lina Zhao, Xiaoyun Ge	2024	1
8	FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma ERJ Open Research ·Jonathan Corren, Fred Reid, Rachel Moate, Eulalia Jiménez, Muhammad Waqas Sadiq, Adam Williams, Mateusz Rytelewski, Sophia Cameron‐Christie, Daniel Muthas, Benjamin Georgi, Dennis E. Brooks, Eva Lindqvist, Chris Kell, Adam Platt, Maria G. Belvisi, Hitesh Pandya	2025	1
9	Late Breaking Abstract - FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD Hitesh Pandya, Patricia Guller, Fred Reid, Sarah Doffman, Lars H. Nordenmark, Ulla Seppälä, Ioannis Psallidas, Rachel Moate, Rebecca Smith, Joanna Kiraga, Eulalia Jiménez, Dennis E. Brooks, Anne‐Maree Kelly, Muhammad Waqas Sadiq, Chris Kell, Maria G. Belvisi, Dave Singh	2024	1

About Chris Kell

Chris Kell is a scholar working on Physiology, Immunology, Surgery, Pulmonary and Respiratory Medicine and Rheumatology, having authored 9 papers that have together received 447 indexed citations. Recurring topics across this work include Asthma and respiratory diseases (6 papers), IL-33, ST2, and ILC Pathways (5 papers), Eosinophilic Esophagitis (4 papers), Respiratory and Cough-Related Research (3 papers), Pediatric health and respiratory diseases (2 papers), Pharmaceutical studies and practices (1 paper), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (1 paper) and Urticaria and Related Conditions (1 paper). The work is most often cited by research in Immunology and Allergy (95 citations), Physiology (306 citations), Immunology (163 citations), Pulmonary and Respiratory Medicine (245 citations) and Emergency Medical Services (38 citations). Chris Kell has collaborated with scholars based in United Kingdom, Singapore and Sweden. Frequent co-authors include Dewei She, Raffaella Faggioni, Chad K. Oh, Edward Piper, Néstor A. Molfino, Robert Niven, Christopher E. Brightling, Gregory P. Geba, Richard May and Kevin R. Flaherty. Their work appears in journals such as European Respiratory Journal, ERJ Open Research, American Journal of Respiratory and Critical Care Medicine, Advances in Therapy and British Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact